Latest news with #ERCP
Time of India
24-05-2025
- Business
- Time of India
CM approves land allocation to forest dept to accelerate ERCP project
1 2 Jaipur: Chief minister Bhajan Lal Sharma approved allocation of 1,102.72 hectares of land to the forest department under the forest land diversion process, aiming to fast-track the Ramjal Setu Link Project (RSLP), also known as the Eastern Rajasthan Canal Project (ERCP). The approval covers four separate proposals involving the diversion of forest land impacted by key components of the RSLP. These include the under-construction Ramgarh and Mahlpur barrages, along with the Navnera-Galwa-Bisalpur-Isarda Link Project. According to officials, the approved land includes 427.59 hectares in Kishanganj tehsil, 284.09 hectares in Chhabra tehsil, and 362.95 hectares in Chhipabarod tehsil—all located in Baran district. Additionally, 28.08 hectares of non-forest land from the Reserved Land Fund in Alwar district will be allocated to the Forest Department free of cost. Officials described the move as a critical step toward accelerating the implementation of the ERCP, a flagship water infrastructure project designed to meet the irrigation and drinking water needs of eastern Rajasthan. tnn Get the latest lifestyle updates on Times of India, along with Brother's Day wishes , messages and quotes !
News18
16-05-2025
- Politics
- News18
Issues Become Complex When States Are Governed By Different Parties: CR Patil On Water-Sharing Disputes
Last Updated: When asked about the Cauvery water dispute, Patil replied that the matter is still ongoing. Jal Shakti Minister CR Patil mentioned that inter-state water disputes often arise because political leaders and party figures push for allocations beyond their entitlement. 'When states are governed by different parties, the issue becomes more complex. Political leaders often demand more water than they are authorised to, which eventually creates an environment that, if any commitment is made for less than that, then the people there become against it," he said. Patil was speaking at the Powering Bharat Summit 2025, organised by Network18 in collaboration with Moneycontrol, News18 India, and CNBC Awaaz. He noted that while the government has no authority over the positions taken by political parties, it is focusing on key development projects under the Modi government's jurisdiction, such as the Ken-Betwa project, expected to be completed by 2030, and the Parvati-Kalisindh-Chambal Eastern Rajasthan Canal Project (PKC-ERCP). According to the Ministry of Jal Shakti, the ERCP link project aims to provide drinking and industrial water to 13 districts of eastern Rajasthan, Malwa, and Chambal regions of Madhya Pradesh. An MoU was signed by the two states for this project last year. Meanwhile, the Ken-Betwa Link Project, with a cost of over 44,000 crore rupees, is expected to benefit millions in rural areas of Madhya Pradesh and Uttar Pradesh. First Published: May 16, 2025, 19:12 IST
Medscape
09-05-2025
- Health
- Medscape
No Benefit to ERCP With Sphincterotomy in Pancreas Divisum
SAN DIEGO — In treating pancreas divisum, the common use of endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy showed no significant benefit over a sham procedure, suggesting that patients can be spared the intervention, which can carry risks of its own. 'This is a topic that has been debated for decades,' said first author Gregory A. Coté, MD, Division Head, professor of medicine, Division of Gastroenterology & Hepatology, Oregon Health & Science University, in Portland, Oregon. 'Many doctors believe the procedure helps and offer it because we have limited options to help our patients, whereas others believe the procedure is harmful and doesn't help,' he explained in a press briefing for the late-breaking study, presented at Digestive Disease Week (DDW) 2025. The study's findings supported the latter argument. 'Patients who underwent ERCP with sphincterotomy were just as likely as those who did not have this procedure to develop acute pancreatitis again,' Coté reported. While clinical guidelines currently recommend ERCP as treatment for pancreas divisum, 'these guidelines are likely to change based on this study,' he said. Pancreas divisum, occurring in about 7%-10% of people, is an anatomic variation that can represent an obstructive risk factor for acute recurrent pancreatitis. The common use of ERCP with minor papilla endoscopic sphincterotomy to treat the condition is based on prior retrospective studies showing that in patients who did develop acute pancreatitis, up to 70% with the treatment never developed acute pancreatitis again. However, there have been no studies comparing the use of the treatment with a control group. Coté and colleagues conducted the multicenter SHARP trial, in which 148 patients with pancreas divisum were enrolled between September 2018 and August 2024 and randomized to receive either ERCP with minor papilla endoscopic sphincterotomy (n = 75) or a sham treatment (n = 73). The patients, who had a median age of 51 years, had a median of 3 acute pancreatitis episodes prior to randomization. With a median follow-up of 33.5 months (range, 6-48 months), 34.7% of patients in the ERCP arm experienced an acute pancreatitis incident compared with 43.8% in the sham arm, for a hazard ratio of 0.83 after adjusting for duct size and the number of episodes, which was not a statistically significant difference ( P = .27). A subgroup analysis further showed no indication of a treatment effect based on factors including age, diabetes status, sex, alcohol or tobacco use, or other factors. 'Compared with a sham ERCP group, we found that minor papillotomy did not reduce the risk of acute pancreatitis, incident chronic pancreatitis, endocrine pancreatic insufficiency or diabetes, or pancreas-related pain events,' Coté said. The findings are particularly important because the treatment itself is associated with some risks, he added. 'Ironically, the problem with this procedure is that it can cause acute pancreatitis in 10%-20% of patients and may instigate other issues later,' such as the development of scarring of the pancreas related to incisions in the procedure. 'No one wants to offer an expensive procedure that has its own risks if it doesn't help,' Coté said. Based on the findings, 'pancreas divisum anatomy should no longer be considered an indication for ERCP, even for idiopathic acute pancreatitis,' he concluded.
Yahoo
29-01-2025
- Business
- Yahoo
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis, 2025-2030 - Gallstone Prevalence Expected to Surge, Boosting ERCP Adoption
Endoscopic Retrograde Cholangiopancreatography Market Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Endoscopic Retrograde Cholangiopancreatography Market Size, Share & Trends Analysis by Product, Procedure Type, End-use, and Region, 2025-2030" report has been added to global endoscopic retrograde cholangiopancreatography market size was estimated at USD 2.17 billion in 2024 and is anticipated to grow at a CAGR of 8.26% from 2025 to 2030. The growth of the endoscopic retrograde cholangiopancreatography (ERCP) market is primarily driven by the rising incidence of pancreatic and biliary diseases, such as gallstones, pancreatitis, and bile duct obstructions. As the population ages and lifestyles change, these conditions are becoming more prevalent, increasing the demand for ERCP procedures. A study published in Clinical Gastroenterology and Hepatology in February 2024 estimates a global gallstone prevalence of 6%, with higher rates in females and in South America. The incidence of gallstones is expected to rise sharply over the forecast period, further fueling ERCP demand. Advancements in endoscopic technology have improved ERCP safety and efficacy. For example, in January 2023, Advantech introduced the MIO-5377R single-board computer, designed to enhance endoscopic performance, reliability, and functionality. Innovations such as high-definition imaging, improved endoscope maneuverability, and advanced therapeutic accessories have made ERCP a more precise and effective diagnostic and treatment tool, attracting both healthcare providers and patients. The growing adoption of minimally invasive surgical techniques is also driving ERCP demand. According to the American Cancer Society's annual report (January 2024), an estimated 41,630 new liver cancer cases will be diagnosed in the U.S. Liver cancer is more prevalent in Southeast Asia and sub-Saharan Africa, where it is the most common cancer type, with over 800,000 new cases diagnosed globally each year. It is also a leading cause of cancer-related deaths, claiming over 700,000 lives annually. The high burden of cholangiocarcinoma and hepatocellular carcinoma is expected to further boost ERCP adoption for early cancer detection. Increased awareness of the benefits of early diagnosis and treatment of pancreatic and biliary diseases has heightened demand for minimally invasive procedures. In October 2023, the Biliary Atresia Awareness Committee launched a campaign under the auspices of Gauteng Provincial Solid Organ Transplant Division and the University of the Witwatersrand at Charlotte Maxeke Academic Hospital. The initiative aimed to raise awareness and support for children with biliary atresia, a rare and life-threatening liver disease affecting infants. It focused on educating diverse populations, providing resources to affected families, advancing diagnostic research, and fostering global medical collaboration. An aging population is another key driver of market growth. As chronic conditions such as coagulopathy and anemia become more common in older adults, the demand for ERCP and related procedures, including those requiring blood transfusions, is rising. Currently, over 40 million people in the U.S. are aged 65 or older, a number expected to double by 2050. Japan, home to the world's largest geriatric population, presents significant growth opportunities. According to the WHO, the geriatric population is projected to reach 22% globally by 2050. Healthcare organizations are increasingly investing in research and partnerships to drive innovation. A Optica Publishing Group study (July 2022) highlighted the development of a photoacoustic imaging endoscope probe, which can be inserted into a medical needle as small as 0.6 mm in diameter. Researchers also suggested AI could accelerate imaging procedures. Strategic initiatives by market players, including mergers, acquisitions, and product launches, are expected to further propel growth. For instance, in April 2022, Olympus partnered with EndoClot Plus, a company specializing in hemostasis technologies. EndoClot PHS, a nonthermal, nontraumatic solution for gastrointestinal bleeding, is a key product in its portfolio. This partnership aims to improve accessibility to EndoClot PHS, enabling gastroenterologists to stop bleeding quickly and effectively during procedures. Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listing for you to stay ahead of the curve Key Attributes Report Attribute Details No. of Pages 120 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $2.17 billion Forecasted Market Value (USD) by 2030 $3.51 billion Compound Annual Growth Rate 8.2% Regions Covered Global Key Topics Covered Chapter 1. Methodology and Scope1.1. Market Segmentation and Scope1.2. Segment Definitions1.3. Research Methodology1.4. Information Procurement1.5. Information or Data Analysis1.6. Market Formulation & Validation1.7. Model Details1.8. List of Secondary Sources1.9. List of Primary Sources1.10. Objectives Chapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.3. Regional Outlook2.4. Competitive Insights Chapter 3. Endoscopic Retrograde Cholangiopancreatography Market Variables, Trends & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.3. Endoscopic Retrograde Cholangiopancreatography Market Analysis Tools Chapter 4. Endoscopic Retrograde Cholangiopancreatography Market: Product Estimates & Trend Analysis4.1. Segment Dashboard4.2. Endoscopic Retrograde Cholangiopancreatography Market: Product Movement Analysis4.3. Endoscopic Retrograde Cholangiopancreatography Market by Product Outlook (USD Million)4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following4.5. Endoscopes4.6. Endotherapy Devices4.7. Visualization Systems4.8. Energy Devices4.9. Others Chapter 5. Endoscopic Retrograde Cholangiopancreatography Market: Procedure Estimates & Trend Analysis5.1. Segment Dashboard5.2. Endoscopic Retrograde Cholangiopancreatography Market: Procedure Movement Analysis5.3. Endoscopic Retrograde Cholangiopancreatography Market by Procedure Outlook (USD Million)5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following5.5. Biliary Sphincterotomy5.6. Biliary Stenting5.7. Biliary Dilatation5.8. Pancreatic Sphincterotomy5.9. Pancreatic Duct Stenting5.10. Pancreatic Duct Dilation Chapter 6. Endoscopic Retrograde Cholangiopancreatography Market: End Use Estimates & Trend Analysis6.1. Segment Dashboard6.2. Endoscopic Retrograde Cholangiopancreatography Market: End Use Movement Analysis6.3. Endoscopic Retrograde Cholangiopancreatography Market by End Use Outlook (USD Million)6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following6.5. Hospitals6.6. Outpatient Facilities Chapter 7. Endoscopic Retrograde Cholangiopancreatography Market: Regional Estimates & Trend Analysis7.1. Regional Dashboard7.2. Regional Endoscopic Retrograde Cholangiopancreatography Market Movement Analysis7.3. Endoscopic Retrograde Cholangiopancreatography Market: Regional Estimates & Trend Analysis by Technology & End Use7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following7.5. North America7.6. Asia-Pacific7.7. Latin America7.8. Middle East & Africa Chapter 8. Competitive Landscape8.1. Market Participant Categorization8.2. Key Company Profiles8.2.1. Olympus Corporation8.2.2. CONMED Corporation8.2.3. Boston Scientific Corporation8.2.4. Medtronic plc8.2.5. Telemed System, Inc.8.2.6. AMBU, Inc.8.2.7. Fujifilm Holdings Corporation8.2.8. Hobbs Medical, Inc.8.2.9. Cook Group8.2.10. Streis plc8.2.11. HOYA Group8.2.12. Karl Storz SE & Co. KG For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Endoscopic Retrograde Cholangiopancreatography Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data
